Search Results - "Pillai, Sureshkumar"

KDM1A inhibition augments the efficacy of rapamycin for the treatment of endometrial cancer by Venkata, Prabhakar Pitta, Chen, Yihong, Alejo, Salvador, He, Yi, Palacios, Bridgitte E., Loeffel, Ilanna, Liu, Junhao, Pratap, Uday P., Gray, Gabrielle, Achuthan Pillai, Sureshkumar Mulampurath, Zou, Yi, Lai, Zhao, Suzuki, Takayoshi, Viswanadhapalli, Suryavathi, Palakurthi, Srinath, Tekmal, Rajeshwar R., Vadlamudi, Ratna K., Kost, Edward, Sareddy, Gangadhara R.

“…Endometrial cancer (EC) often exhibit aberrant activation of PI3K/Akt/mTOR signaling and targeted therapies using mTOR inhibitors showed limited success. The…”
Get full text

LIF/LIFR oncogenic signaling is a novel therapeutic target in endometrial cancer by Tang, Weiwei, Ramasamy, Kumaraguruparan, Pillai, Sureshkumar M. A., Santhamma, Bindu, Konda, Swapna, Pitta Venkata, Prabhakar, Blankenship, Logan, Liu, Junhao, Liu, Zexuan, Altwegg, Kristin A., Ebrahimi, Behnam, Pratap, Uday P., Li, Xiaonan, Valente, Philip T., Kost, Edward, Sareddy, Gangadhara R., Vadlamudi, Ratna K., Nair, Hareesh B., Tekmal, Rajeshwar R., Viswanadhapalli, Suryavathi

“…Endometrial cancer (EC) is the fourth most common cancer in women. Advanced-stage EC has limited treatment options with a poor prognosis. There is an unmet…”
Get full text

Can statins reduce a systemic inflammatory response during pregnancy in an animal model? by Neuhoff, Barbara K., Pillai, Sureshkumar, Pearcy, Tia, Costantine, Maged M., Prewit, Egle Bytautiene

Get full text

Effects of lactation and mother-offspring interaction on oxytocin and postpartum cardiovascular health in murine model by Pearcy, Tia, Pillai, Sureshkumar, Davis, Logan, Kersh, Kaitlin D., Aminkeng, Ashlie-Chellsie, Aune, Gregory, Stuebe, Alison M., Prewit, Egle Bytautiene

Get full text

989 Effect of statins on lipopolysaccharide-induced fetal inflammation by Prewit, Egle, Achuthan Pillai, Sureshkumar Mulampurath, La Rosa, Mauricio, Costantine, Maged M.

Get full text

Serum exosomal microRNA pathway activation in placenta accreta spectrum (PAS) pathophysiology and detection by Munoz, Jessian L., Einerson, Brett D., Ireland, Kayla E., Silver, Robert M., Pillai, Sureshkumar, Sherman, Lauren, Rameshwar, Pranela, Prewit, Egle Bytautiene, Ramsey, Patrick S.

Get full text

Development, validation and application of VEGF as a novel biomarker for Placenta Accreta Spectrum (PAS) by Munoz, Jessian L., Einerson, Brett D., Ireland, Kayla E., Silver, Robert M., Hernandez, Brian, Pillai, Sureshkumar, Prewit, Egle Bytautiene, Ramsey, Patrick S.

Get full text

Correction: Utilizing metformin to prevent metabolic syndrome due to androgen deprivation therapy (ADT): a randomized phase II study of metformin in non-diabetic men initiating ADT for advanced prostate cancer by Mahalingam, Devalingam, Hanni, Salih, Serritella, Anthony V., Fountzilas, Christos, Michalek, Joel, Hernandez, Brian, Sarantopoulos, John, Datta, Paromitta, Romero, Ofelia, Achutan Pillai, Sureshkumar Mulampurath, Kuhn, John, Pollak, Michael, Thompson, Ian M.

Get full text

Utilizing metformin to prevent metabolic syndrome due to androgen deprivation therapy (ADT): a randomized phase II study of metformin in non-diabetic men initiating ADT for advanced prostate cancer by Mahalingam, Devalingam, Hanni, Salih, Serritella, Anthony V, Fountzilas, Christos, Michalek, Joel, Hernandez, Brian, Sarantopoulos, John, Datta, Paromitta, Romero, Ofelia, Pillai, Sureshkumar Mulampurath Achutan, Kuhn, John, Pollak, Michael, Thompson, Ian M

“…Androgen deprivation therapy (ADT) can lead to metabolic syndrome (MS) and is implicated in ADT-resistance. Metformin showed antineoplastic activity through…”
Get full text

Abstract 3269: Metformin to prevent metabolic syndrome associated with androgen deprivation therapy (ADT): Metabolic analysis from a placebo-controlled study of metformin in non-diabetic men initiating ADT for advanced prostate cancer (PCa) by Mahalingam, Devalingam, Hanni, Salih, Fountzilas, Christos, Michalek, Joel, Sarantopoulos, John, Pillai, Sureshkumar Mulampurath Achuthan, Kuhn, John, Pollak, Michael, Thompson, Ian

“…Background: ADT results in metabolic syndrome, characterized by hyperinsulinemia, insulin resistance and obesity. The hyperinsulinemia may result in ADT…”
Get full text

Abstract 1253: Therapeutic targeting of endometrial cancer with novel LIFR inhibitor EC359 by Tang, Weiwei, Ramasamy, Kumaraguruparan, Pillai, Sureshkumar M., Santhamma, Bindu, Konda, Swapna, Vekata, Prabhakar P., Blankenship, Logan, Liu, Junhao, Liu, Zexuan, Altwegg, Kristin A., Ebrahimi, Behnam, Pratap, Uday P., Li, Xiaonan, Kost, Edward, Sareddy, Gangadhara R., Vadlamudi, Ratna K., Nair, Hareesh B., Tekmal, Rajeshwar R., Viswanadhapalli, Suryavathi

“…Background: Endometrial cancer (EC) is the fourth most common cancer in women. Approximately 80% of EC belong to the endometroid-EC subtype and are driven by…”
Get full text

Metformin to treat prostate cancer (PCa) and prevent metabolic syndrome associated with androgen deprivation therapy (ADT): Results of a randomized double-blind placebo-controlled study of metformin in non-diabetic men initiating ADT for advanced PCa by Mahalingam, Devalingam, Salih, Hanni, Fountzilas, Christos, Michalek, Joel, Sarantopoulos, John, Datta, Paromita, Romero, Ofelia, Mulampurath Achutan Pillai, Sureshkumar, Kuhn, John G., Pollak, Michael N., Thompson, Ian Murchie

“…Abstract only e16502 Background: ADT results in metabolic syndrome, characterized by hyperinsulinemia, insulin resistance and obesity. The hyperinsulinemia may…”
Get full text